Zimmer Biomet Holdings Inc (NYSE:ZBH) – Stock analysts at Cantor Fitzgerald issued their FY2017 earnings estimates for shares of Zimmer Biomet in a research note issued on Sunday. Cantor Fitzgerald analyst C. Bijou expects that the medical equipment provider will post earnings of $8.03 per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. Cantor Fitzgerald also issued estimates for Zimmer Biomet’s FY2018 earnings at $8.15 EPS.
Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). The business had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. The company’s revenue for the quarter was down .8% on a year-over-year basis. During the same quarter last year, the firm posted $1.79 EPS.
Zimmer Biomet (NYSE:ZBH) opened at $124.19 on Wednesday. The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.88. The firm has a market cap of $25,150.00, a P/E ratio of 38.69, a P/E/G ratio of 1.96 and a beta of 1.15. Zimmer Biomet has a twelve month low of $108.03 and a twelve month high of $133.49.
A number of institutional investors have recently modified their holdings of the stock. QUANTRES ASSET MANAGEMENT Ltd lifted its stake in Zimmer Biomet by 547.4% in the fourth quarter. QUANTRES ASSET MANAGEMENT Ltd now owns 12,300 shares of the medical equipment provider’s stock worth $1,484,000 after acquiring an additional 10,400 shares during the last quarter. Atlantic Trust Group LLC lifted its stake in Zimmer Biomet by 32.2% in the third quarter. Atlantic Trust Group LLC now owns 28,171 shares of the medical equipment provider’s stock worth $3,298,000 after acquiring an additional 6,860 shares during the last quarter. AXA lifted its stake in Zimmer Biomet by 26.3% in the third quarter. AXA now owns 412,845 shares of the medical equipment provider’s stock worth $48,340,000 after acquiring an additional 85,861 shares during the last quarter. Steward Partners Investment Advisory LLC purchased a new position in Zimmer Biomet in the third quarter worth approximately $140,000. Finally, Jana Partners LLC lifted its stake in Zimmer Biomet by 16.6% in the third quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock worth $545,932,000 after acquiring an additional 662,497 shares during the last quarter. Institutional investors own 85.92% of the company’s stock.
The company also recently declared a quarterly dividend, which will be paid on Monday, January 29th. Investors of record on Friday, December 29th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $0.96 dividend on an annualized basis and a yield of 0.77%. Zimmer Biomet’s dividend payout ratio is currently 29.91%.
ILLEGAL ACTIVITY WARNING: “Equities Analysts Offer Predictions for Zimmer Biomet Holdings Inc’s FY2017 Earnings (ZBH)” was first posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.themarketsdaily.com/2018/01/10/equities-analysts-offer-predictions-for-zimmer-biomet-holdings-incs-fy2017-earnings-zbh.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.